Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CASP2 | P42575 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
| ▸ | TP53BP1 | Q12888 | 4/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19750382 | 1.00 | MEN1 (0.43) | MEN1KMT2AALDH1A1SMN1; SMN2CASP2 | |
| SCHEMBL22280402 | 0.98 | MEN1 (0.45) | MEN1KMT2AALDH1A1SMN1; SMN2CASP2 | |
| SCHEMBL18272880 | 0.94 | TP53BP1 (0.42) | MEN1KMT2AALDH1A1SMN1; SMN2CASP2 | |
| SCHEMBL23518488 | 0.90 | MEN1 (0.52) | MEN1KMT2AALDH1A1SMN1; SMN2CASP2 | |
| SCHEMBL18272799 | 0.86 | HPGD (0.41) | MEN1KMT2AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL26504642 | 0.83 | MEN1 (0.47) | MEN1KMT2AALDH1A1SMN1; SMN2CASP2 | |
| SCHEMBL22144552 | 0.82 | MEN1 (0.45) | MEN1KMT2AALDH1A1SMN1; SMN2CASP2 | |
| SCHEMBL26749121 | 0.82 | MEN1 (0.68) | MEN1KMT2AALDH1A1SMN1; SMN2CASP2 | |
| SCHEMBL24193577 | 0.82 | MEN1 (0.45) | MEN1KMT2AALDH1A1SMN1; SMN2CASP2 | |
| SCHEMBL25475907 | 0.82 | MEN1 (0.45) | MEN1KMT2AALDH1A1SMN1; SMN2CASP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207415-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | DBD THERAPEUTICS, LLC | 2024-06-27 | — | — | US | disclosed |
| US-11787778-B2 | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor | MONTELINO THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787778-B2 | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor | MONTELINO THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230241227-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | DBD THERAPEUTICS, LLC | 2023-08-03 | — | — | US | disclosed |
| US-20230241227-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | DBD THERAPEUTICS, LLC | 2023-08-03 | — | — | US | disclosed |
| US-20230134817-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | DBD THERAPEUTICS, LLC | 2023-05-04 | — | — | US | disclosed |
| US-20230132823-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | DBD THERAPEUTICS, LLC | 2023-05-04 | — | — | US | disclosed |
| US-20230132823-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | DBD THERAPEUTICS, LLC | 2023-05-04 | — | — | US | disclosed |
| US-20210292298-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | DBD THERAPEUTICS, LLC | 2021-09-23 | — | — | US | disclosed |
| US-20200239430-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | MONTELINO THERAPEUTICS, LLC (US) | 2020-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787778-B2 | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor | AR, ADRM1, PSMA3 | MEN1 4512/4885KMT2A 1282/4885ALDH1A1 2421/4885 |
| US-20230241227-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | AR, ADRM1, PSMA3 | MEN1 4516/4885KMT2A 1286/4885ALDH1A1 2547/4885 |
| US-20240207415-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | AR, ADRM1, PSMA3 | MEN1 4512/4885KMT2A 1282/4885ALDH1A1 2421/4885 |
| US-20230134817-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | AR, ADRM1, PSMA3 | MEN1 4512/4885KMT2A 1282/4885ALDH1A1 2421/4885 |
| US-20200239430-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | AR, ADRM1, PSMA3 | MEN1 4516/4885KMT2A 1286/4885ALDH1A1 2547/4885 |
| US-20210292298-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | AR, ADRM1, PSMA3 | MEN1 4516/4885KMT2A 1286/4885ALDH1A1 2547/4885 |
| US-20230132823-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | AR, ADRM1, PSMA3 | MEN1 4512/4885KMT2A 1282/4885ALDH1A1 2421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.